Patent ID: RE44048

Claim:
A method of treating inflammation or an inflammation-associated disorder in a subject, said method comprising administering to the subject having or susceptible to such inflammation or inflammation-associated disorder, a therapeutically-effective amount of a compound of Formula I wherein R 1 is phenyl substituted at a substitutable position with one or more radicals selected from halo, C 1 -C 10 -alkyl, and sulfamyl wherein R 2 is selected from hydrido, C 1 -C 6 -haloalkyl, cyano, carboxy, C 1 -C 6 -alkoxycarbonyl, C 1 -C 6 -carboxyalkyl, C 1 -C 6 -alkoxy, C 1 -C 6 -alkylthio, aminocarbonyl, aminocarbonyl-C 1 -C 6 -alkyl, C 1 -C 6 -N-alkylaminocarbonyl, N-arylaminocarbonyl, C 1 -C 6 -N,N-dialkylaminocarbonyl, C 1 -C 6 -N-alkyl-N-aryl-aminocarbonyl, and C 1 -C 6 -hydroxyalkyl; wherein R 3 is selected from hydrido, C 1 -C 10 -alkyl, halo, cyano, C 1 -C 6 -alkoxy, C 1 -C 6 -hydroxyalkyl, C 1 -C 6 -alkylthio, and C 1 -C 6 -alkylsulfonyl; wherein R 4 is selected from aryl-C 2 -C 6 -alkenyl, aryl, C 3 -C 7 -cycloalkyl, C 3 -C 7 -cycloalkenyl and five to ten membered heterocyclic; wherein R 4 is optionally substituted at a substitutable position with one or more radicals selected from halo, C 1 -C 6 -alkylthio, C 1 -C 6 -alkylsulfinyl, C 1 -C 10 -alkyl, C 1 -C 6 -alkylsulfonyl, cyano, carboxyl, C 1 -C 6 -alkoxycarbonyl, aminocarbonyl, C 1 -C 6 -haloalkyl, hydroxyl, C 1 -C 6 -alkoxy, C 1 -C 6 -hydroxyalkyl, C 1 -C 6 -haloalkoxy, sulfamyl, C 1 -C 6 -N-alkylaminocrbonyl, amino, C 1 -C 6 -N-alkylamino, C 1 -C 6 -N,N-dialkylamino, five or six membered heterocyclic, nitro, and and wherein R 7 is hydrido; wherein aryl wherever occurring means phenyl, naphthyl, tetrahydronaphthyl, indene, biphenyl, provided R 2 and R 3 are not identical radicals selected from hydrido, carboxyl and ethoxycarbonyl; further provided that R 2 is not carboxyl or methyl when R 3 is hydrido and when R 4 is phenyl; further provided that R 4 is not triazolyl when R 2 is methyl; further provided that R 4 is not aralkenyl when R 2 is carboxyl, aminocarbonyl or ethoxycarbonyl; further provided that R 4 is not phenyl when R 2 is methyl and R 3 is carboxyl; further provided that R 4 is not 4-chlorophenyl when R 2 is methyl and R 3 is bromo; further provided that R 4 is not unsubstituted thienyl when R 2 is trifluoromethyl; and further provided that R 4 is aryl substituted with sulfamyl when R 1 is phenyl not substituted with sulfamyl; and further provided the compound is not 4-[5-(3-fluoro-4-methoxyphenyl)-3-(difluoromethyl)-1H-pyrazol-1yl]benzenesulfonamide; or a pharmaceutically-acceptable salt thereof.